November 19, 2024

Clarametyx Bioscience Recognized as “Infectious Disease Innovation of the Year” In 2024 BioTech Breakthrough Awards

Clarametyx Bioscience Recognized as “Infectious Disease Innovation of the Year” In 2024 BioTech Breakthrough Awards

Annual awards program recognizes innovation in the global life sciences and biotechnology industries

COLUMBUS, Ohio – November 19, 2024 – Clarametyx Biosciences Inc. (“Clarametyx”), a biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilms, has been named “Infectious Disease Innovation of the Year” as part of the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Clarametyx was recognized for the development of a novel immune-enabling anti-biofilm antibody technology, which is designed to destroy the scaffold-like structure of the bacterial biofilm to allow the immune system and/or antibiotics to more effectively eliminate bacteria. This approach is particularly compelling given it targets a universal component of the biofilm structure, rendering it effective across many different types of bacterial infections. Clarametyx’s technology works alongside today’s antibiotics to enable rapid resolution of bacterial infections, potentially reducing the dose and duration of the antibiotics required which helps to slow the rates of antibiotic resistance. In addition to addressing active infections, the company’s approach could serve as an early treatment, working to prevent the biofilm from forming as well as reducing transformation to chronic infections.

“We believe our approach represents a new way to look at addressing challenging chronic bacterial infections in a way that not only improves patient outcomes, but also supports antimicrobial stewardship,” said David Richards, CEO of Clarametyx Biosciences. “We are grateful for the recognition as part of the BioTech Breakthrough Awards for 2024, which helps to magnify the significance of our mission and supports continued momentum for our development pipeline, which is focused on challenging chronic respiratory disease.”

The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the world’s top companies, solutions and products in the life sciences and biotechnology markets today. This year’s program attracted thousands of nominations from over 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.

“Clarametyx is rapidly advancing clinical and non-clinical studies to optimize their groundbreaking technology platform. A major contributing factor to the rise in antibiotic resistance is the increasing use of high doses and repeated courses of antibiotics for bacterial infections, particularly those infections associated with biofilms,” said Bryan Vaughn, Managing Director, BioTech Breakthrough. “Clarametyx’s therapeutic platform represents a completely novel approach to biofilm-associated bacterial infections and a potential breakthrough in combating antimicrobial resistance, a significant public health threat. Congratulations on winning the ‘Infectious Disease Innovation of the Year’ award!”

About Clarametyx Biosciences

Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines for life-threatening bacterial infections associated with biofilms, with a near-term focus on challenging respiratory infections. For more information, visit us on the web or on LinkedIn.

About BioTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Immunology, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughAwards.com

Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.

Media Contact:

Kellie Hotz
khotz@clarametyx.com

# # #

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.